COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Combination of Ibrutinib and As2O3 in the Treatment of CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02757040
Recruitment Status : Unknown
Verified April 2016 by Peking University People's Hospital.
Recruitment status was:  Not yet recruiting
First Posted : April 29, 2016
Last Update Posted : April 29, 2016
Beijing Hospital
Information provided by (Responsible Party):
Peking University People's Hospital

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018